Comparative Study of Different Sources of Pertussis Toxin (PT) as Coating Antigens in IgG Anti-PT Enzyme-Linked Immunosorbent Assays
Open Access
- 1 January 2012
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 19 (1) , 64-72
- https://doi.org/10.1128/cvi.05460-11
Abstract
In an effort to improve the reliability and reproducibility of serological assays forBordetella pertussis, a collaborative study was conducted to compare four different sources of pertussis toxin (PT) as coating antigens in the immunoglobulin G (IgG) anti-PT enzyme-linked immunosorbent assay (ELISA). Four sources of PT were used as coating antigens in the IgG anti-PT ELISA in four different testing laboratories (labs A to D) to determine whether the different antigen preparations and different laboratories influenced assay results. A panel of 60 sera consisting of deidentified human specimens from previous vaccination trials of healthy adults and infants and clinical specimens from outbreak settings was tested. In the four laboratories, each sample was tested three times with the four PT antigens according to the standard coating optimization and IgG anti-PT ELISA testing procedures used in that laboratory. Differences among the antigens, as well as intra- and interlaboratory variability, were evaluated. Excellent agreement was observed with the test panel results among the four antigens within each laboratory. Concordance correlation coefficient (rc) measurements among the different antigens ranged from 0.99, 0.99 to 1.00, 1.00, and 0.97 to 1.00 for labs A to D, respectively. The comparisons between pairs of laboratories also indicated a high degree of concordance for each PT preparation, withrcmeasurements between 0.90 and 0.98, 0.93 and 0.99, 0.92 and 0.98, and 0.93 and 0.99 for antigens 1 to 4, respectively. Relatively minor differences in results were observed among laboratories or among antigens, suggesting that the four PT antigens are quite similar and could be considered for acceptance in harmonized immunoassays used for serodiagnosis or vaccine evaluation.Keywords
This publication has 28 references indexed in Scilit:
- EUVAC.NET collaborative study: Evaluation and standardisation of serology for diagnosis of pertussisJournal of Immunological Methods, 2011
- What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratoriesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010
- Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccineJournal of Medical Microbiology, 2010
- Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: Meeting at the CrossroadsVaccine, 2010
- Antibody Response Patterns to Bordetella pertussis Antigens in Vaccinated (Primed) and Unvaccinated (Unprimed) Young Children with PertussisClinical and Vaccine Immunology, 2010
- Development and Analytical Validation of an Immunoassay for Quantifying Serum Anti-Pertussis Toxin Antibodies Resulting from Bordetella pertussis InfectionClinical and Vaccine Immunology, 2009
- Characterization of Reference Materials for Human Antiserum to Pertussis Antigens by an International Collaborative StudyClinical and Vaccine Immunology, 2009
- International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007Vaccine, 2008
- Comparison of Serological and Real-Time PCR Assays To Diagnose Bordetella pertussis Infection in 2007Journal of Clinical Microbiology, 2008
- Establishment of Diagnostic Cutoff Points for Levels of Serum Antibodies to Pertussis Toxin, Filamentous Hemagglutinin, and Fimbriae in Adolescents and Adults in the United StatesClinical and Vaccine Immunology, 2004